Marijuana is on track to move from the federal government’s most restrictive drug category to a more permissive one, under a sweeping directive from the White House that could reshape everything from medical research to small business balance sheets. President Trump’s new executive order instructs federal agencies to complete the process of shifting cannabis to Schedule III, a change that would still keep it illegal for recreational use at the federal level but would treat it more like other controlled prescription drugs.
The move caps years of pressure on Washington to reconcile federal law with state markets and medical practice, while opening a new round of questions about how far this reform really goes. I see it as a pivotal but partial reset, one that eases some of the most punitive consequences of Schedule I status without delivering the full legalization many advocates expected.
The executive order that forces the rescheduling question
The centerpiece of this shift is Executive Order 14370, formally titled “Increasing Medical Marijuana and Cannabidiol Research,” which directs federal agencies to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In the order, President Trump acknowledges that marijuana’s current classification has blocked scientific study and constrained legitimate medical use, and he instructs the attorney general and the Drug Enforcement Administration to complete the rulemaking needed to reclassify it. The order also explicitly ties marijuana policy to cannabidiol, or CBD, signaling that the administration wants a unified framework for both substances rather than the patchwork that has emerged since Congress carved out hemp products.
The new directive builds on earlier federal steps that had already revived rescheduling efforts and set priorities for research and CBD policy. Prior executive action described in Dec, Oops, We Did It Again, Executive Action Revives Federal Marijuana Rescheduling Efforts and Sets Research and CBD Policy Priorities laid the groundwork for agencies to revisit cannabis scheduling and clarify how CBD products fit into federal law, even as it cautioned that such guidance would not create private rights or entitlements for industry participants, according to Dec. Executive Order 14370 now goes further by explicitly ordering completion of the rescheduling process, turning what had been a tentative policy exploration into a binding instruction to move marijuana into Schedule III.
How Schedule III changes the legal and business landscape
Rescheduling marijuana to Schedule III would not make it fully legal, but it would dramatically change how the federal government treats cannabis businesses and medical programs. Schedule III substances are still controlled, yet they can be prescribed, researched, and manufactured under regulated conditions, and they are not subject to the same tax penalties that have crippled state-licensed dispensaries. Legal analysts note that moving cannabis into this category would allow cultivators and manufacturers to deduct ordinary business expenses, which could significantly increase profit margins if business practices are updated accordingly, a point underscored in Dec.
The order also intersects with broader economic and financial access questions that have dogged the cannabis sector. By directing the attorney general to reschedule marijuana to Schedule III under the Controlled Substances Act, President Trump is effectively inviting banks, insurers, and mainstream lenders to reassess their risk calculations, since Schedule III drugs are part of the conventional pharmaceutical economy. Commentators tracking The Schedule III Era, Everything You Need, Know About Cannabis Rescheduling argue that this shift could open doors to traditional business loans, more efficient processing, and normalized tax treatment, even though cannabis would still not be “finally federally legal,” as explained in Schedule III Era. In practice, I expect that means larger, better capitalized operators will be quickest to benefit, while smaller dispensaries may need time and legal support to retool their compliance and accounting systems.
Research, CBD, and the unfinished federal framework
One of the most immediate effects of the executive order is on scientific research and CBD regulation, areas that have been constrained by marijuana’s Schedule I status even as consumer markets exploded. In the EO, President Trump explicitly recognizes that marijuana’s continuing classification under Schedule I impedes research and limits its medical uses, and he directs agencies to prioritize studies that can clarify both therapeutic benefits and risks. The order’s full text, described in Executive Order and Medicare CBD Program, also links marijuana rescheduling to a broader federal effort to expand access to CBD products through Medicare and other health programs, as outlined in Executive Order and.
The research push does not start from scratch. In October, President Joe Biden asked the Department of Health and Human Services and the Drug Enfor to review marijuana’s status, a move that set a formal process of rescheduling marijuana already underway and gave scientific agencies a central role in reassessing cannabis risks and benefits, according to the Introduction. Executive Order 14370 now layers on a more prescriptive mandate, tying that scientific review to concrete regulatory deadlines and explicitly naming CBD as a priority. At the same time, legal commentary on the new order stresses that, While the directive is sweeping, it does not itself change the Controlled Substances Act or immediately authorize new products; instead, it sets the stage for potential legislative activity in 2026 and leaves agencies to fill in many of the details, as explained in While.
Hemp, CBD products, and safety standards
Beyond marijuana itself, the executive order forces regulators to confront the messy reality of hemp and CBD products that have flooded the market since Congress removed hemp from the Controlled Substances Act. The Impact on “Hemp” Product Standards section of recent legal analysis notes that this statutory change led to the proliferation of hemp and CBD products in the marketplace, including items that pose serious health risks, and that the administration now wants to tighten oversight of these goods, as detailed in Impact. By pairing marijuana rescheduling with a directive to improve hemp product standards, the White House is signaling that it sees cannabis and CBD as part of a single regulatory ecosystem rather than separate silos.
That approach could have far reaching consequences for retailers and manufacturers who built business models around lightly regulated CBD oils, gummies, and wellness products. The executive order’s focus on Increasing Medical Marijuana and Cannabidiol Research suggests that future rules may distinguish more sharply between pharmaceutical grade CBD used in clinical settings and over the counter items sold in gas stations or online marketplaces, as reflected in Executive Order. I expect that companies operating in the gray areas of the hemp market will face new testing, labeling, and distribution requirements, while medical researchers may gain clearer pathways to study CBD formulations in controlled trials.
Workplaces, safety rules, and the limits of reform
Even as marijuana moves toward Schedule III, the executive order leaves many day to day rules unchanged, especially in workplaces and safety sensitive industries. Legal experts tracking nuclear sector regulations point out that President Trump, in directing rescheduling, also acknowledged that the continuing classification under Schedule I had impeded research, yet he did not automatically alter Nuclear Regulatory Commission fitness for duty requirements, which still treat marijuana use as a potential safety concern until the completion of the rulemaking, as described in Schedule. That tension illustrates a broader pattern: federal drug policy is shifting, but sector specific rules will lag until regulators rewrite them.
More From The Daily Overview
Grant Mercer covers market dynamics, business trends, and the economic forces driving growth across industries. His analysis connects macro movements with real-world implications for investors, entrepreneurs, and professionals. Through his work at The Daily Overview, Grant helps readers understand how markets function and where opportunities may emerge.
